Suraksha Diagnostic AGM: All resolutions passed, director re-appointment sees 10% dissent
- Shareholders approved all five resolutions at the 21st AGM held on September 22, 2026
- Final dividend of ₹0.50 per equity share declared for FY26
- Re-appointment of director Satish Kumar Verma passed with 90.08% support, seeing 9.92% dissent
- Institutional investors cast 22.70% of their votes against the director's re-appointment
- Total votes polled across resolutions ranged between 36.69 million and 42.34 million
*this image is generated using AI for illustrative purposes only.
Suraksha Diagnostic Limited shareholders approved all five resolutions at the 21st Annual General Meeting (AGM) held on September 22, 2026. The meeting confirmed the adoption of FY26 financial statements and the declaration of a final dividend of ₹0.50 per equity share.
The virtual meeting, conducted via video conferencing from 11:30 am to 12:17 pm IST, saw all ordinary and special business items passed by requisite majority. Dr. Somnath Chatterjee chaired the session, while Ritu Mittal, Joint Managing Director and CEO, briefed members on company affairs and growth during FY26.
Key Resolutions Passed
The following agenda items were adopted by the shareholders:
| Item | Description | Resolution Type | Result |
|---|---|---|---|
| 1 | Adoption of audited standalone financial statements for FY26 | Ordinary | Passed |
| 2 | Adoption of audited consolidated financial statements for FY26 | Ordinary | Passed |
| 3 | Declaration of final dividend of ₹0.50 per equity share | Ordinary | Passed |
| 4 | Re-appointment of Satish Kumar Verma as Non-Executive Non-Independent Director | Ordinary | Passed |
| 5 | Ratification of remuneration for Cost Auditor M/s. S. Chhaparia & Associates for FY27 | Ordinary | Passed |
Meeting Proceedings and Governance
The CFO highlighted the company's financial performance and growth trajectory for the fiscal year ended March 31, 2026. All directors attended the meeting except Satish Kumar Verma, who was absent due to personal reasons. Sandhya Malhotra, Practicing Company Secretary at M/s Manish Ghia and Associates, served as the scrutinizer to oversee remote e-voting and voting during the meeting.
Statutory Registers and relevant documents were accessible electronically throughout the session. The recording of the meeting is available on the company's website. Voting results will be submitted to stock exchanges in compliance with SEBI Listing Regulations.
Voting Results Breakdown
The company disclosed detailed voting results pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A total of 62,150 shareholders were on record as of September 15, 2026. The following table summarizes the vote distribution for each resolution:
| Resolution | Votes In Favour (%) | Votes Against (%) | Total Votes Polled |
|---|---|---|---|
| 1. Standalone Financials | 99.9989% | 0.0011% | 42,338,135 |
| 2. Consolidated Financials | 99.9990% | 0.0010% | 42,338,135 |
| 3. Final Dividend | 99.9992% | 0.0008% | 42,338,135 |
| 4. Director Re-appointment | 90.0827% | 9.9173% | 36,694,164 |
| 5. Cost Auditor Remuneration | 99.9988% | 0.0012% | 42,338,135 |
What the Numbers Show
While four of the five resolutions received near-unanimous support (>99.99%), Resolution 4 regarding the re-appointment of Mr. Satish Kumar Verma saw significant dissent. Approximately 9.92% of the votes polled were cast against this resolution. This dissent was driven primarily by Public-Institutions, where 22.70% of the votes polled were against the re-appointment, compared to just 0.03% among Public-Non Institutions. Promoters voted in favour but abstained from voting on this specific item relative to their full holding, casting 18.49 million votes out of their 24.14 million holdings.
Historical Stock Returns for Suraksha Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.57% | +4.36% | +6.25% | +33.97% | +10.71% | -17.72% |
How will the 9.92% dissent against Satish Kumar Verma's re-appointment, particularly from institutional investors, impact the board's governance strategy and potential director reshuffles in FY27?
What specific growth initiatives did CEO Ritu Mittal highlight during the AGM that are expected to drive Suraksha Diagnostic's performance in the upcoming fiscal year?
Given the promoter abstention on the director re-appointment resolution, what underlying concerns or strategic misalignments might exist between the promoter group and public institutions?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
